Prevalence and clinical associations of myositis antibodies in a large cohort of interstitial lung diseases

Sofia A. Moll1 *, Mark G. J. P. Platenburg1, Anouk C. M. Platteel2, Adriane D. M. Vorselaars1, Montse Janssen Bonàs1, Raisa Kraaijvanger1, Claudia Roodenburg-Benschop1, Bob Meek2, Coline H. M. van Moorsel1, Jan C. Grutters1,3

1 Department of Pulmonology, St. Antonius Hospital Nieuwegein, Centre for Interstitial Lung Diseases, Nieuwegein, The Netherlands, 2 Department of Medical Microbiology and Immunology, St. Antonius Hospital Nieuwegein, Nieuwegein, The Netherlands, 3 Division Heart & Lungs, University Medical Centre Utrecht, Utrecht, The Netherlands

* s.moll@antoniusziekenhuis.nl

Abstract

Background

Serologic testing for autoantibodies is recommended in interstitial lung diseases (ILDs), as connective tissue diseases (CTDs) are an important secondary cause. Myositis antibodies are associated with CTD-ILD, but clinical associations with other ILDs are unclear. In this study, associations of myositis antibodies in various ILDs were evaluated.

Methods

1463 ILD patients and 116 healthy subjects were screened for myositis antibodies with a line-blot assay on serum available at time of diagnosis. Additionally, bronchoalveolar lavage fluid (BALf) was analysed.

Results

A total of 394 patients demonstrated reactivity to at least one antibody, including anti-Ro52 (36.0%), anti-Mi-2β (17.3%) and anti-Jo-1 (10.9%). Anti-Jo-1 (OR 6.4; p<0.100) and anti-Ro52 (OR 6.0; p<0.001) were associated with CTD-ILD, but clinical associations with other ILDs are unclear. In this study, associations of myositis antibodies in various ILDs were evaluated.

Conclusion

In conclusion, novel associations of antibody Mi-2β with fibrotic ILD were found. Furthermore, serum anti-Mi-2β was associated with a histological UIP pattern and presence of anti-
and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Abbreviations: ANA, Antinuclear antibody; ASS, Anti-synthetase syndrome; ATS, American Thoracic Society; BALf, Bronchoalveolar lavage fluid; CA 15–3, Cancer antigen 15–3; CC16, Clara cell secretory protein; CCL18, CC chemokine ligand 18; COP, Cryptogenic organizing pneumonia; CPFE, Combined pulmonary fibrosis and emphysema; CTD, Connective tissue disease; DIP, Desquamative interstitial pneumonia; DM, Dermatomyositis; Dlco, Diffusing capacity of the lung for carbon monoxide; ERS, European Respiratory Society; FVC, Forced vital capacity; FEV1, Forced expiratory volume in 1 second; HP, Hypersensitivity pneumonitis; HRCT, High-resolution computed tomography; IBM, Inclusion body myositis; IIP, Idiopathic interstitial pneumonia; ILD, Interstitial lung disease; IMNM, Immune mediated necrotizing myopathy; IP, Interstitial pneumonia; IPAF, Interstitial pneumonia with autoimmune features; IPF, Idiopathic pulmonary fibrosis; MAA, Myositis associated antibody; MSA, Myositis specific antibody; NSIP, Non-specific interstitial pneumonia; PFT, Pulmonary function test; PM, Polymyositis; RA, Rheumatoid arthritis; SLE, Systemic lupus erythematosus; SP-D, Surfactant protein D; Ssc, Systemic sclerosis; UIP, Usual interstitial pneumonia; YKL-40, Chitinase-3-like protein 1.

Mi-2β in BALf. Possibly, anti-Mi-2β could be implemented as a future diagnostic biomarker for fibrotic ILD.

Introduction

Interstitial lung diseases (ILDs) are a group of heterogeneous, diffuse parenchymal lung diseases, characterized by inflammation and/or fibrosis of the pulmonary interstitium. ILDs can be idiopathic or secondary to known causes including environmental exposures, drugs or connective tissue disease (CTD) [1–4]. In 15% of patients with ILD an underlying CTD is identified [3, 5]. Distinguishing CTD related ILD (CTD-ILD) from other ILD is challenging as clinical, functional, radiological and pathological characteristics could be similar [6]. Moreover, an interstitial pneumonia (IP) may be the first or lone clinical manifestation of an associated CTD [4, 6]. In general, outcomes on treatment response to immunosuppressive therapy and survival are better in CTD-ILD compared to the majority of other ILDs [5–10]. Thus, discriminating these conditions in the diagnostic work-up is essential.

Serologic testing for autoantibodies by a myositis blot is recommended in pulmonary fibrosis suspected for an underlying CTD and includes myositis specific antibodies (MSA) and myositis associated antibodies (MAA) [1, 3, 4, 6, 11–16]. MSA and MAA are found in patients with idiopathic interstitial myopathies but also occur in patients with rheumatic diseases including CTD-ILDs [3–6, 11–23]. Presence of t-RNA synthase antibodies are strongly associated with ILD in antisynthetase syndrome (ASS), dermatomyositis (DM) and polymyositis (PM) [6, 20, 23–25]. Furthermore, a combination of t-RNA synthase antibodies and anti-Ro52/SSA is characterized by chronic and severe ILD [6, 19].

Myositis antibodies have also been identified in hypersensitivity pneumonitis (HP) and idiopathic IPs [11, 16, 26–28]. Although it is known that an IP can precede future CTD [3, 6], evidence is scarce on the clinical relevance of antibody positivity in patients meeting established criteria for other ILD. Therefore, it remains unclear how positive serologic testing in these ILDs should be interpret in clinical practice. Possibly, certain antibodies could be more associated with ILD features such as fibrosis than other characteristics of CTD.

To date, no major studies have compared myositis antibody positivity between CTD-ILD and other ILD. The aim of this study was to evaluate prevalence and clinical associations of myositis antibodies in these patients to enhance the diagnostic performance of serologic testing.

Methods

Patient selection

A retrospective cohort study was performed at the St Antonius ILD Centre of Excellence Nieuwegein, a tertiary ILD centre in the Netherlands. The majority of ILD patients were diagnosed between 2000 and 2019. The myositis blot used at our hospital was first introduced in 2012. All patients diagnosed with ILD before 2012, have not undergone a diagnostic myositis blot during their diagnostic work up. Subjects who had been tested for myositis antibodies during diagnostic work-up were evaluated. In addition, ILD patients who at first were not screened for myositis antibodies during their diagnostic work-up, were evaluated for the presence of antibodies in serum collected at date of diagnosis by a line-blot assay, run between 05–2019 and 07–2019. In addition, serum of healthy, non-ILD blood donors were screened for myositis antibodies as controls. For details on serum storage and sampling, see S1 File.
Diagnosis of ILD was assessed according to official ATS/ERS recommendations in a multidisciplinary discussion with an ILD pulmonologist, experienced thoracic radiologist, and a pathologist, when required [29]. All patients with pulmonary fibrosis were screened for an underlying CTD by the pulmonologist and referred to the rheumatologist for further diagnostic work-up if a CTD was suspected. During the multidisciplinary discussion, antibody reactivity was mainly interpreted by the rheumatologist. Furthermore, patients were referred to the rheumatologist during follow-up if an (ongoing) inflammation, suspected for autoimmune activity, was observed.

Patients were classified as having a CTD-ILD or ILD without established CTD (non-CTD-ILD). Patients were checked for any revisions of the ILD diagnosis during two years of follow-up, as an IP can precede an associated CTD often within two years after onset of disease [3, 6]. CTD-ILDs included antisynthetase syndrome (ASS), Sjögren’s syndrome, rheumatoid arthritis associated ILD (RA-ILD), systemic sclerosis (Ssc), dermatomyositis (DM), polymyositis (PM), immune mediated necrotizing myopathy (IMNM), inclusion body myositis (IBM), overlap myositis, systemic lupus erythematosus (SLE), mixed CTD and other CTD-ILD. Non-CTD-ILDs included idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis (HP), unclassifiable idiopathic interstitial pneumonia (Unclassifiable IIP), non-specific interstitial pneumonia (NSIP), cryptogenic organizing pneumonia (COP) and other ILD.

Patients with reactivity on a positive level against one or more antibodies were included for analysis. Only the first sample was included if more than one sample of a given patient was present. Subjects with solely weakly positive or negative antibody reactivity were excluded.

Baseline characteristics included pulmonary function tests, which were performed according to ATS/ERS recommendations [29]. Serum pneumoproteins including cancer antigen 15–3 (CA 15–3), CC chemokine ligand 18 (CCL18), Clara cell secretory protein (CC16), chitinase-3-like protein 1 (YKL-40) and surfactant protein D (SP-D) were evaluated as well. Characteristics on high-resolution computed tomography (HRCT) scans and in lung biopsies (when available) were classified as a pattern of usual interstitial pneumonia (UIP), probable UIP, indeterminate UIP or alternative diagnosis according to recent ATS/ERS recommendations [29]. Furthermore, prevalence of clinical symptoms was evaluated in patients with CTD-ILD. Autoimmune phenomena included for analysis were arthralgia, arthritis, Raynaud’s phenomenon, sicca complaints, mechanic’s hands, myalgia and muscle weakness.

The study was approved by the St Antonius institutional review under protocol number 842002003 and patients provided written informed consent for research purposes.

Determination of antibodies
Antibodies were detected in serum using a line-blot assay (EUROLINE Autoimmune Inflammatory Myopathies, EUROIMMUN, Lübeck, Germany), in collaboration with Biognost. The assay identified MSA including antibodies against Jo-1, EJ, OJ, PL-7, PL-12, Mi-2α, Mi-2β, TIF1-γ, MDA5, NXP2 and SAE1 and MAA, including antibodies against Ku, PM/Scl-75, PM/Scl-100 and Ro52. Analysis of the immunoblot strips was performed with the EUROLINEScan software (EUROIMMUN, Lübeck, Germany) according to manufacturer’s recommendations as described for the EUROLINE Autoimmune Inflammatory Myopathies line blot assay. Strips were scored as negative, weakly positive and positive, which corresponds with intensity levels of respectively 0–10, 11–25 and >25. Antibody reactivity on a positive and weakly positive intensity level was separately evaluated.

Statistical analysis
Baseline characteristics were expressed as numbers and percentages or mean and standard deviation. Continuous and categorical variables were tested with a student’s T-test/one-way
ANOVA and Chi-Square test/Fisher’s Exact test respectively. A binary logistic regression analysis was performed in CTD-ILD and non-CTD-ILD for testing antibody level and association, expressed as general odds ratios. Survival plots were created using Kaplan Meier curves. Survival time was expressed in months from date of diagnosis. Survival was censored after death or lung transplantation. The statistical analysis was performed by software IBM SPSS version 24.0. A p-value less than 0.05 was considered as statistically significant.

Results

Baseline characteristics

A total of 1463 ILD patients were screened for myositis antibodies. One hundred CTD-ILD and 294 non-CTD-ILD patients were positive for at least one antibody and were included in this study. Baseline characteristics are listed in Table 1 and per ILD diagnosis in the

| Subjects | All | CTD-ILD | Non-CTD-ILD | P < 0.05 |
|----------|-----|---------|-------------|---------|
| N        | 394 | 100     | 294         |         |
| Age      | 63.6 (11.2) | 59.1 (11.5) | 65.1 (10.7) | < 0.001 |
| Sex (m), % | 242 (61.4) | 46 (46.0) | 196 (66.7) | < 0.001 |
| History of smoking, % | 272 (68.7) | 56 (56.0) | 212 (72.4) | 0.007 |

Pulmonary function test\(^a\)

| Test | All | CTD-ILD | Non-CTD-ILD | P < 0.05 |
|------|-----|---------|-------------|---------|
| FVC  | 81.0 (20.1) | 80.4 (23.2) | 81.2 (19.0) | 0.751 |
| FEV1 | 83.3 (37.9) | 86.3 (67.9) | 82.3 (19.8) | 0.571 |
| DLCO | 46.9 (16.2) | 49.3 (15.0) | 46.2 (16.5) | 0.101 |

Pneumoprotein\(^b\)

| Protein | All | CTD-ILD | Non-CTD-ILD | P < 0.05 |
|---------|-----|---------|-------------|---------|
| CA 15–3 | 64.9 (64.2) | 51.2 (46.8) | 69.8 (68.9) | 0.003 |
| CC16    | 20.2 (26.1) | 17.2 (46.8) | 21.2 (15.1) | 0.410 |
| CCL18   | 174.2 (112.7) | 164.7 (93.2) | 177.3 (118.3) | 0.331 |
| SP-D    | 113.4 (194.1) | 108.7 (175.1) | 115.1 (200.8) | 0.768 |
| YKL-40  | 148.4 (133.7) | 140.8 (122.0) | 151.2 (137.8) | 0.724 |

HRCT scan\(^c\)

| Diagnosis | All | CTD-ILD | Non-CTD-ILD | P < 0.05 |
|-----------|-----|---------|-------------|---------|
| UIP       | 96 (24.9) | 11 (11.3) | 85 (29.4) | < 0.001 |
| Probable UIP | 47 (12.2) | 7 (7.2) | 40 (13.8) | 0.084 |
| Indeterminate | 75 (19.4) | 24 (24.7) | 51 (17.6) | 0.126 |
| Alternative | 168 (43.5) | 55 (56.7) | 113 (39.1) | 0.002 |

Histopathology\(^d\)

| Diagnosis | All | CTD-ILD | Non-CTD-ILD | P < 0.05 |
|-----------|-----|---------|-------------|---------|
| UIP       | 24 (20.5) | - | 24 (27.0) | 0.002 |
| Probable UIP | 12 (10.3) | 5 (17.9) | 7 (7.9) | 0.129 |
| Indeterminate | 20 (17.1) | 5 (17.9) | 15 (16.9) | 0.902 |
| Alternative | 61 (52.1) | 18 (64.3) | 43 (48.3) | 0.140 |

Data are expressed as mean and standard deviation or numbers and percentage within the diagnosis group.

CTD = connective tissue disease; ILD = interstitial lung disease; non-CTD-ILD = ILD without established CTD; FVC = forced vital capacity; FEV1 = forced expiratory volume in 1 second; DLCO = diffusing capacity of the lung for carbon monoxide; CA 15–3 = cancer antigen 15–3; CCL18 = CC chemokine ligand 18; CC16 = Clara cell secretory protein; SP-D = surfactant protein D; YKL-40 = chitinase-3-like protein 1; UIP = usual interstitial pneumonia

\(^a\) n = 383, data expressed mean and standard deviation in percentage of predicted

\(^b\) n = 383, data expressed as mean and standard deviation in kU/l (CA 15–3) or ng/ml (CC16, CCL18, SP-D, YKL-40)

\(^c\) n = 386, data expressed as numbers and percentage

\(^d\) n = 117, data expressed as numbers and percentage

\(^e\) p < 0.05, differences between CTD-ILD and non-CTD-ILD are calculated by a two-side unpaired T-test/One way Analysis of variance for continuous variables or Chi-Square test/Fisher’s Exact test for dichotomous variables.

https://doi.org/10.1371/journal.pone.0277007.t001
supplementary data (S1 and S2 Tables in S1 File). Of CTD-ILD patients, a revision on the initial diagnosis (all formerly diagnosed as NCIP) was made in 15 (15%) patients. Mean duration between initial diagnosis and revision was 12.3 months (SD 8.8; range 2–23 months).

Significant differences between CTD-ILD and non-CTD-ILD were found for age (p<0.001), sex (p<0.001), smoking history (p = 0.007) and serum CA 15–3 (p = 0.003). Furthermore, radiological (p<0.001) and histopathological (p = 0.002) UIP patterns were predominantly observed in non-CTD-ILDs (range 4.2–82.4%) including IPF.

In CTD-ILD patients, presence of one or more autoimmune phenomena were common: arthralgia 75% (n = 75), arthritis 27% (n = 27), Raynaud’s phenomenon 44% (n = 44), sicca complaints 51% (n = 51), mechanic’s hands 11% (n = 11), myalgia 55% (n = 55) and muscle weakness 36% (n = 36). Prevalence of autoimmune phenomena per subtype CTD-ILD are listed in S1 Table in S1 File. Between groups, prevalence of arthritis was significantly different (p<0.001), with highest prevalence in patients with RA-ILD (n = 11; 100%).

Of CTD-patients, 86 patients (86%) showed non-UIP radiological patterns, i.e. patterns of probable UIP, indeterminate UIP or alternative diagnosis. In detail, radiological patterns of NSIP (n = 47), OP (n = 23), ground glass nodules (n = 4), lymphocytic interstitial pneumonitis (LIP; n = 3) and other radiological dominant patterns, including cysts (n = 1) and nodules (n = 1) were described. For non-CTD-ILD patients, non-UIP radiological patterns were seen in 69.4% of patients (n = 204). In detail, radiological patterns of NSIP (67.2%), OP (11.8%), ground glass nodules (11.3%), LIP (1.0%), emphysema (3.4%), cysts (1.5%) and nodules (3.9%) were observed.

Frequencies of myositis antibodies in patients with ILD

Antibody prevalence was evaluated for all ILD, 116 healthy controls (Table 2) and per ILD diagnosis (S3 and S4 Tables in S1 File). On a positive intensity level, the most prevalent antibodies in ILD were Ro52 (36.0%) and Mi-2β (17.3%), followed by Jo-1 (10.9%) and SRP (7.4%, Table 2). Antibody prevalence was significantly higher in ILD compared to controls except for antibodies EJ, MDA5, Mi-2α, NXP2 and OJ. Anti-Ro52 reactivity was high in ASS (83.9%) and Sjögren’s syndrome (92.3%, S3 Table in S1 File) but also observed in unclassifiable IIP, NSIP and COP (range 27.3–54.8%; S4 Table in S1 File). Prevalence of antibodies Mi-2β, SRP and Ku was significantly higher in non-CTD-ILD compared to CTD-ILD (all p<0.05, see Table 2), in particular in IPF (respectively 26.5%, 11.8% and 8.8%) and unclassifiable IIP (respectively 17.9%, 14.2% and 7.5%; S4 Table in S1 File). Mi-2β antibodies were observed in HP as well (26.4%).

Associations between antibody level and ILD

Associations between antibody reactivity and ILD were evaluated (Table 3). At the positive intensity level, strong associations were found of antibodies Jo-1 (OR 6.4; p<0.001), PL-12 (OR 3.4; p = 0.007) and Ro52 (OR 6.0; p<0.001) with CTD-ILD. Furthermore, odds ratios of less than one were found with antibodies Mi-2β (OR 0.3; p = 0.002), SRP (OR 0.2; p = 0.026) and Ku (OR 0.1; near-significant: p = 0.058) with CTD-ILD. Expressed as a reversed odds ratio (1/OR), corresponding ratios were 2.7, 5.3 and 7.1 respectively, indicating odds in favour of non-CTD-ILD. A sub analysis of CTD-ILD compared to IPF showed strong associations of antibodies Mi-2β (OR 0.2; 1/OR 5.0; p = 0.001), Ku (OR 0.1; 1/OR 10; p = 0.034) and SRP (OR 0.1; 1/OR 7.7; p = 0.013; S5 Table in S1 File) with IPF. Similarly, antibodies Mi-2β (OR 3.2; p = 0.015), Ku (OR 5.0 p = 0.046) and TIF1-γ (OR 16.7; p = 0.008) were associated with unclassifiable IIP compared to CTD-ILD. Mi-2β antibody was associated with HP compared to CTD-ILD as well (OR 5.9; p<0.001).
Associations between antibody level and radiological and histological characteristics

Next, associations of antibodies with radiological and histological patterns were evaluated. Anti-SAE1 was associated with a radiological UIP pattern (OR 3.2; p = 0.036). Anti-Ro52 was associated with both radiological (OR 2.7; \(p < 0.001\)) and histological non-UIP patterns (OR 0.16; 1/OR 6.3; \(p = 0.005\); see Table 4). Interestingly, antibody Mi-2\(\beta\) was strongly associated with a histological UIP pattern (OR 6.5; \(p < 0.001\)) but not significantly associated with a radiological UIP pattern. Concerning non-UIP radiological patterns (n = 47) in serum Mi-2\(\beta\) positive ILD patients, patterns of NSIP (83.8%), OP (12.8) and ground glass nodules (10.6%) were most prevalent. However, evaluation of ILD patients classified per radiological pattern (from UIP to alternative diagnosis) showed that the association of anti-Mi-2\(\beta\) with histological UIP persisted within each radiological group (OR range 4.3–10, all \(p < 0.05\)), indicating that the association of serum Mi-2\(\beta\) antibodies with histological UIP was independent of the patients’ corresponding radiological pattern. Other antibodies were not significantly associated with radiological patterns.

Survival analysis

A survival analysis was performed to explore the prognostic value of antibody reactivity against Mi-2\(\beta\) in ILD patients. Overall, mean follow-up was 66.7 months (SD 50.5). Median survival of CTD-ILD patients (47 months) was significantly higher compared to non-CTD-ILD patients.
ILD patients with reactivity against Mi-2β showed no difference in survival (median 31.0 months) compared to patients without reactivity against Mi-2β (median 29.1 months; hazard ratio 0.835; 95% CI 0.442–1.575; p = 0.577). Within the CTD-ILD group, no difference was observed in survival between patients with and without reactivity against Mi-2β (p = 0.993). For the non-CTD-ILD group, no significant difference between patients with and without reactivity against Mi-2β was observed as well (p = 0.352).

Table 3. Associations of myositis antibodies with ILD patients.

| Antibody | CTD-ILD (n = 100) | Non-CTD-ILD (n = 294) |
|----------|------------------|-----------------------|
|          | Number Neg | Number Weak pos | Number Pos | Number Neg | Number Weak pos | Number Pos | OR p | 95% Crb | p*   |
| EJ       | 95        | -                | 5          | 289        | -                | 5          | 3.0  | 0.86–10.76 | 0.084 |
| Jo-1     | 72        | 1                | 27         | 271        | 7                | 16         | 6.4  | 3.25–12.42 | <0.001 |
| Ku       | 98        | 1                | 1          | 262        | 13               | 19         | 0.1  | 0.02–1.07  | 0.058 |
| MDA5     | 97        | 1                | 2          | 277        | 11               | 6          | 1.0  | 0.19–4.80  | 0.952 |
| Mi-2α     | 99       | -                | 1          | 285        | 4                | 5          | 0.6  | 0.07–4.99  | 0.616 |
| Mi-2β     | 91        | 2                | 7          | 211        | 22               | 61         | 0.3  | 0.12–0.60  | 0.002 |
| NXP2     | 95        | 1                | 4          | 287        | 4                | 3          | 4.0  | 0.89–18.3  | 0.071 |
| OJ        | 99        | -                | 1          | 284        | 4                | 6          | 0.5  | 0.06–4.02  | 0.497 |
| PL-12     | 89        | -                | 11         | 278        | 6                | 10         | 3.4  | 1.41–8.36  | 0.007 |
| PL-7      | 95        | -                | 5          | 270        | 5                | 19         | 0.8  | 0.27–2.06  | 0.574 |
| PM/Scl 100 | 87    | -                | 13         | 260        | 14               | 20         | 1.9  | 0.93–4.07  | 0.078 |
| PM/Scl 75 | 86       | 1                | 13         | 249        | 12               | 33         | 1.1  | 0.57–2.27  | 0.707 |
| Ro52      | 31        | 2                | 67         | 208        | 11               | 75         | 6.0  | 3.63–9.89  | <0.001 |
| SAE1      | 98        | 2                | -          | 271        | 9                | 14         | -    | 0.6       | 0.13–2.89 | 0.538 |
| SRP       | 90        | 8                | 2          | 232        | 35               | 27         | 0.2  | 0.04–0.82  | 0.026 |
| TIF1-γ     | 96       | 3                | 1          | 265        | 6                | 23         | 0.1  | 0.02–0.90  | 0.039 |

CTD = connective tissue disease; ILD = interstitial lung disease; non-CTD-ILD = ILD without established CTD
* OR: odds ratio for positive level (OR p); odds ratio for weak positive level (OR wp).
b 95% confidence interval of odds ratio's
* Logistic regression analysis of CTD versus other patients with positive, weak positive and negative antibody, with predicted probability for CTD-ILD.
Antibody expression in bronchoalveolar lavage fluid (BALf)

An analysis was performed in BALf with regard to the association of antibody Mi-2β with histological UIP pattern. First, BALfs were retrieved of patients with serum Mi-2β antibodies on a positive intensity level and of a subset of patients without Mi-2β antibodies. BALf was tested for the presence of anti-Mi-2β by the line-blot assay (see S1 File). To determine the extent of possible leakage of blood plasma products to the alveoli, an albumin BALf/serum ratio was calculated and used as an indicator for antibody leakage. Nine serum Mi-2β positive ILD and

| Antibody | UIP (n = 24) | Non-UIP (n = 93) | OR p | 95% CIb | p* |
|----------|-------------|-----------------|------|---------|----|
| EJ       | 24          | -               | 92   | -       | 1  |
| Jo-1     | 21          | 1               | 2    | 83      | 1  |
| Ku       | 23          | 1               | -    | 91      | 1  |
| MDA5     | 23          | 1               | -    | 91      | 1  |
| Mi-2α     | 22          | 1               | 1    | 88      | 3  |
| Mi-2β     | 10          | 3               | 11   | 77      | 3  |
| NXP2     | 24          | -               | -    | 92      | -  |
| OJ        | 23          | 1               | -    | 92      | -  |
| PL-12     | 22          | 2               | -    | 81      | 1  |
| PL-7      | 21          | 1               | 2    | 86      | 2  |
| PM/Scl 100 | 22       | -               | 2    | 78      | 3  |
| PM/Scl 75 | 18          | 2               | 4    | 76      | 2  |
| Ro52      | 20          | 1               | 3    | 45      | 6  |
| SAE1      | 22          | -               | 2    | 90      | 1  |
| SRP       | 15          | 7               | 2    | 78      | 11 |
| TIF1-γ    | 19          | 3               | 2    | 87      | 1  |

UIP = usual interstitial pneumonia
* OR: odds ratio for positive level (OR p); odds ratio for weakly positive level (OR wp).
* 95% confidence interval of odds ratio’s
* Logistic regression analysis of histological UIP versus non UIP patients with positive, weakly positive and negative antibody, with predicted probability for UIP.

https://doi.org/10.1371/journal.pone.0277007.t004
eleven serum Mi-2β negative ILD with available BALfs were included (Table 5). Of serum Mi-2β positive ILD, one patient (IPF) demonstrated Mi-2β reactivity on a positive level in BALf, one patient (HP) on a weakly positive level and three (n = 2 HP and n = 1; RA-ILD) on a borderline weakly positive level (intensity level 6–10). Serum Mi-2β negative ILD patients did not show any Mi-2β reactivity in BALf. No differences were found in albumin BALf/serum ratios between serum Mi-2β positive and negative ILD patients (p = 0.849). In addition, albumin BALf/serum ratios in serum Mi-2β positive ILD were not different as well between subjects with and without Mi-2β reactivity in BALf (p = 0.568). Mi-2β reactivity on a combined (borderline) weakly positive and positive level in BALf was strongly associated with concurrent serum Mi-2β reactivity (r = 0.64; p = 0.002). Mi-2β reactivity on a positive level only in BALf was not significantly associated with serum Mi-2β reactivity.

### Discussion

In this study, we evaluated prevalence, clinical characteristics and associations of myositis antibodies in a large cohort of ILD. Antibodies Jo-1 and Ro52 were strongly associated with CTD-ILD. Strikingly, we demonstrated stronger associations of anti-Mi-2β positivity with IPF, HP and unclassifiable IIP compared to CTD-ILD. Furthermore, Mi-2β antibody was strongly associated with a histological pattern of UIP. Interestingly, anti-Mi-2β reactivity was detected in BALf and correlated with serum Mi-2β reactivity in ILD. No differences were found in
survival rates between ILD patients with and without serum Mi-2β reactivity. To date, the clinical value of positive myositis antibodies in other ILDs including idiopathic IP remains unclear. Possibly, testing of autoantibody Mi-2β in particular could be used as a diagnostic biomarker for fibrotic ILD in clinical practice.

Antibodies against t-RNA synthetases and Ro52 were demonstrated in various ILDs. Antibody Jo-1 is considered as a predictor for ILD and was observed in 27% of CTD-ILD, compared to 30–50% found in DM with ILD [6, 20]. Prevalence of MSA was high in non-CTD-ILD compared to studies with idiopathic IP, in which 6.6–24% of the subjects showed MSA including Jo-1, EJ, NXP-2, PL-7, TIF1-γ and SRP [11, 16, 26]. Contrary, antibody PL-12 was infrequently observed in our IPF cohort (1.5%) compared to an IPF study (5.3%) [27]. Furthermore, patients with idiopathic IP and positive for antibodies EJ, PL-7 or PL-12 were radiologically and/or histologically characterized by a pattern of NSIP or UIP [16, 11, 28], which is in agreement with characteristics of IPF and unclassifiable IIP in our cohort. Antibody frequencies of PL-12 and PL-7 in ASS (both 9.7% respectively) were low compared to ASS-ILD studies (range 60–77%) [23, 24, 26]. However, similarities in histological characteristics were observed in anti-PL-12 positive ILD (non-UIP) compared to findings in anti-PL-12 positive ASS (NSIP) [25]. Furthermore, Ro52 antibodies were frequently observed in both our CTD-ILDs (67%) and in a study with CTD-ILDs including PM/DM and Sjogren’s syndrome (60%) [30]. Prevalence of antibody Ro52 in IPF (14.7%) was in congruence with previous IPF research (15.8%) [28].

Novel findings on associations of antibody Mi-2β with fibrotic ILDs were found, in particular IPF. In DM research, Mi-2β antibodies were demonstrated in 4–14% of the subjects and correlated with the presence of an IP [15, 20]. However, Mi-2β antibodies have not been described in patients with IPF, HP or unclassifiable IIP. Our study adds to previous research that serum Mi-2β antibodies are associated with ILDs without established CTD, including idiopathic IPs. In addition, we are the first to demonstrate anti-Mi-2β reactivity in BALf of ILD patients and its strong association with concurrent serum Mi-2β reactivity. It is known that the Mi-2β antigen is part of the NuRD complex, which is regulated by the chromatin remodeling complex gene CDH4 [31]. CDH4 is essential for specification of early B-cell lineage transcriptional program in lymphocytes [32]. Inactivation of the CDH4/NuRD complex in murine models lead to extensive cardiac fibrosis due to de-differentiation of cardiac myocytes [33]. In addition, high expression of Mi-2β was demonstrated in regenerating myofibers in mice. Moreover, Mi-2β expression was higher in muscle biopsies of DM patients, of which one had concurrent serum Mi-2β antibodies as well, compared to healthy controls [34, 35]. It could be hypothesized that the antibodies against Mi-2β are formed during the remodelling process following destruction of cells important for the structural integrity of alveoli, particularly alveolar type II pneumocytes, and release of the NuRD complex. This loss in structural integrity will be compensated by induction of fibrosis. Possibly, antibody Mi-2β could be used as a distinctive and diagnostic biomarker for pulmonary fibrosis with absence of extra thoracic features.

This study was performed with patients whom were all diagnosed by a standardized multidisciplinary discussion in a tertiary ILD centre in the Netherlands. It is the first study to describe prevalence and associations of myositis antibodies in a large cohort of patients with other ILD compared with CTD-ILD and healthy subjects. This retrospective study has some limitations, as selection bias of more severely impaired patients with pulmonary fibrosis is possible in a referral centre. Although pulmonary involvement in CTD often arises within the first two years after onset of disease [6], it might be possible that a diagnosis bias could have occurred, using a two-year cut-off for checking on revisions on the initial ILD diagnosis. It might be possible that, despite multidisciplinary discussion including a rheumatologist, clinical signs suggestive of an underlying CTD have been unnoticed or developed after two years of
onset of ILD. Therefore, clinicians should stay aware for signs suggestive for an underlying CTD in ILD patients during follow-up. Furthermore, overall prevalence of myositis antibodies in both CTD-ILD and other ILD might be overestimated, as only patients with at least one positive myositis antibody were included for analysis.

The findings of this research raise question why autoantibodies are present in idiopathic IP, including IPF. It is acknowledged that IPF is the result of chronic activated fibroblast-myofibroblasts after repetitive damage, leading to tissue remodelling and injury of alveolar type II pneumocytes [36, 37]. The role of inflammation is controversial though, and sometimes described as an epiphenomon or even co-driver of disease [38]. Increased numbers of autoantibody producing plasma cells in human fibrotic lung tissue have been described in multiple studies, summarized in [38]. Production of autoantibodies comes along with the increased expression of immunity- and inflammation-related genes [39], including many B cell related genes [39, 40] and tertiary lymph nodes [38, 41] during development of fibrosis. This supports a model in which autoreactive B cells are continuously primed and allowed to differentiate into plasma cells secreting autoantibodies. These may include long-lived autoreactive plasma cells as well [38], with the ability to survive in the bone narrow and continuously secrete autoantibodies in absence of antigen stimuli. Furthermore, these plasma cells are resistant to immunosuppressive or B-cell depleting therapy [42]. Thus, it could be hypothesized that certain autoantibodies, such as Mi-2β, are continuously produced in idiopathic IP and do not diminish after treatment with immunosuppressive therapy, whereas antibodies in active CTD-ILD would be more likely the result of short-lived autoreactive plasma cells which are sensitive for immunosuppressants. To investigate this hypothesis, a prospective study in CTD-ILD and non-CTD-ILD with multiple testing of Mi-2β antibodies before start and during therapy is imperative. Furthermore, a prospective cohort study is needed to confirm whether antibody positive ILD patients do not develop future autoimmune features of an underlying CTD, as it is known that an IP can precede two years before clinical manifestations of an associated CTD [3, 6].

For future research, it would be interesting to investigate associations with antibody reactivity and therapeutic strategies, including anti-inflammatory drugs, used in patients with CTD-ILD and other ILD. Moreover, it would be interesting to assess whether anti-fibrotic therapy reduces anti-Mi-2β signal during follow-up in ILD. In clinical practice, a novel approach of testing and interpretation of autoantibodies could be implemented. In Ssc related ILD, which is regularly treated by immunosuppressive therapy, the anti-fibrotic drug nintedanib slowed the progression of ILD [43]. Conversely, IPF patients with circulating autoantibodies could possibly be approached as a phenotype, which might be sensitive for the combination of both anti-fibrotic and immunosuppressive drugs.

To date, the proposed classification of IPAF is a research concept and has not been implemented as an official ILD diagnosis yet [44]. It would be interesting for future search to investigate whether non-CTD-ILD patients who have not previously been tested for MSA/MAA and showing reactivity, would have meet the criteria for IPAF in retrospect.

In conclusion, we demonstrated associations of myositis antibodies including anti-Mi-2β in a large cohort of other ILDs compared to CTD-ILD. Possibly, Mi-2β antibody could be used as a diagnostic biomarker for fibrotic ILD in clinical practice.

Supporting information

S1 File.

(DOCX)
Author Contributions

Conceptualization: Sofia A. Moll, Adriane D. M. Vorselaars.

Data curation: Sofia A. Moll, Mark G. J. P. Platenburg, Montse Janssen Bonàs, Raisa Kraaijvanger, Claudia Roodenburg-Benschop.

Formal analysis: Mark G. J. P. Platenburg, Claudia Roodenburg-Benschop.

Funding acquisition: Coline H. M. van Moorsel, Jan C. Grutters.

Investigation: Sofia A. Moll, Coline H. M. van Moorsel, Jan C. Grutters.

Methodology: Sofia A. Moll, Mark G. J. P. Platenburg, Anouk C. M. Platteel, Adriane D. M. Vorselaars, Bob Meek, Coline H. M. van Moorsel, Jan C. Grutters.

Software: Montse Janssen Bonàs, Raisa Kraaijvanger, Claudia Roodenburg-Benschop.

Supervision: Anouk C. M. Platteel, Adriane D. M. Vorselaars, Bob Meek, Coline H. M. van Moorsel, Jan C. Grutters.

Validation: Sofia A. Moll, Raisa Kraaijvanger, Jan C. Grutters.

Visualization: Sofia A. Moll, Bob Meek, Coline H. M. van Moorsel.

Writing – original draft: Sofia A. Moll, Jan C. Grutters.

Writing – review & editing: Sofia A. Moll, Anouk C. M. Platteel, Adriane D. M. Vorselaars, Bob Meek, Coline H. M. van Moorsel, Jan C. Grutters.

References

1. McLean-Tooke A, Moore I, Lake F. Idiopathic and immune-related pulmonary fibrosis: diagnostic and therapeutic challenges. Clin Transl Immunol [Internet]. 2019 Jan 5 [cited 2019 Nov 12]; 8(11):e1086. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31709050 https://doi.org/10.1002/cti2.1086 PMID: 31709050

2. Antoniou KM, Margaritopoulos GA, Tomassetti S, Bonella F, Costabel U, Poletti V. Interstitial lung disease. Eur Respir Rev [Internet]. 2014 Mar 1 [cited 2019 Nov 12]; 23(131):40–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24591661 https://doi.org/10.1183/09059180.0009113 PMID: 24591661

3. Strange C, Highland KB. Interstitial lung disease in the patient who has connective tissue disease. Clin Chest Med [Internet]. 2004 Sep [cited 2019 Nov 12]; 25(3):549–59. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15331191 https://doi.org/10.1016/j.ccm.2004.05.009 PMID: 15331191

4. Stevenson BR, Thompson GA, Watson MC, Bundell CS, Klinken EM, John M, et al. Autoantibodies in interstitial lung diseases. Pathology [Internet]. 2019 Aug [cited 2019 Nov 12]; 51(5):518–23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31230817 https://doi.org/10.1016/j.pathol.2019.03.007 PMID: 31230817

5. Fidler L, Dubbelt I, Kandel S, Fisher JH, Mittoo S, Shapera S. Screening for Myositis Antibodies in Idiopathic Interstitial Lung Disease. Lung [Internet]. 2019 Jun 5 [cited 2019 Nov 12]; 197(3):777–84. Available from: http://link.springer.com/10.1007/s00408-019-00212-9 PMID: 30838494

6. Bahmer T, Romagnoli M, Girelli F, Claussen M, Rabe KF. The use of auto-antibody testing in the evaluation of interstitial lung disease (ILD)—A practical approach for the pulmonologist. Respir Med [Internet]. 2016 Apr [cited 2019 Nov 12]; 113:80–92. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0954611116300154 https://doi.org/10.1016/j.rmed.2016.01.019 PMID: 26921132

7. Ryerson CJ, Vittinghoff E, Lay B, Lee JS, Mooney JJ, Jones KD, et al. Predicting Survival Across Chronic Interstitial Lung Disease. Chest [Internet]. 2014 Apr [cited 2019 Nov 13]; 145(4):723–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24114524

8. Park JH, Kim DS, Park I-N, Jang SJ, Kitaichi M, Nicholson AG, et al. Prognosis of Fibrotic Interstitial Pneumonia. Am J Respir Crit Care Med [Internet]. 2007 Apr 1 [cited 2019 Nov 13]; 175(7):705–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17218621

9. Suda T, Kono M, Nakamura Y, Enomoto N, Kaida Y, Fujisawa T, et al. Distinct prognosis of idiopathic nonspecific interstitial pneumonia (NSIP) fulfilling criteria for undifferentiated connective tissue disease.
(UCTD). Respir Med [Internet]. 2010 Oct [cited 2019 Nov 13]; 104(10):1527–34. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0954611110000207 https://doi.org/10.1016/j.resmed.2010.04.022 PMID: 20483576

10. Raghu G, Anstrom KJ, King TE, Lasky JA, Martinez FJ, Prednisone, Azathioprine, and N-Acetylcysteine for Pulmonary Fibrosis. N Engl J Med [Internet]. 2012 May 24 [cited 2020 Mar 24]; 366(21):1968–77. Available from: http://www.nejm.org/doi/abs/https://doi.org/10.1056/NEJMoa1113354 PMID: 22607134

11. De Sadeleer LJ, De Langehe E, Bodart N, Vigneron A, Bossuyt X, Wuys WA. Prevalence of Myositis-Specific Antibodies in Idiopathic Interstitial Pneumonias. Lung [Internet]. 2018 Jun 12 [cited 2019 Nov 12]; 196(3):329–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29532165 https://doi.org/10.1007/s00408-018-0108-8 PMID: 29532165

12. Fathi M, Vikgren J, Boisjes M, Tylen U, Jorfeldt L, Tomling G, et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum [Internet]. 2008 May 15 [cited 2019 Nov 12]; 59(5):677–85. Available from: http://doi.wiley.com/10.1002/art.23571 PMID: 1843901

13. Papiris SA, Kagouridis K, Bouros D. Serologic evaluation in idiopathic interstitial pneumonias. Curr Opin Pulm Med [Internet], 2012 Sep [cited 2019 Nov 12]; 18(5):433–40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22694920 https://doi.org/10.1097/MCP.0b013e3283660640 PMID: 22694920

14. Saketkoo LA, Ascherman DP, Cottin V, Christopher-Stine L, Danoff SK, Odds C V. Interstitial Lung Disease in Idiopathic Inflammatory Myopathy. Curr Rheumatol Rev [Internet]. 2010 May [cited 2019 Nov 12]; 6(2):108–19. Available from: http://linkinghub.elsevier.com/retrieve/pii/S09546111100120 https://doi.org/10.2174/157339710971300740 PMID: 21941374

15. Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EKL. A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy. Clin Rev Allergy Immunol [Internet], 2017 Feb [cited 2019 Nov 12]; 52(1):1–19. Available from: http://link.springer.com/10.1007/s12016-015-8510-y PMID: 26424665

16. Watanabe K, Handa T, Tanizawa K, Hosono Y, Taguchi Y, Noma S, et al. Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias. Respir Med [Internet]. 2011 Aug [cited 2019 Nov 12]; 105(8):1238–47. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21941374 https://doi.org/10.1016/j.rmed.2011.03.022 PMID: 21514811

17. Hanke K, Brückner CS, Dähnhch C, Huscher D, Komorowski L, Meyer W, et al. Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthritis Res Ther [Internet], 2009 [cited 2019 Nov 12]; 11(1):R22. Available from: http://arthritis-research.biomedcentral.com/articles/10.1186/ar2614 PMID: 1920901

18. Lhote R, Grenier P, Haroche J, Miyara M, Boussouar S, Mathian A, et al. Characterization of Interstitial Lung Disease Associated With Anti-Ribonucleoprotein Antibodies. J Clin Rheumatol [Internet]. 2019 Aug 13 [cited 2019 Nov 12];1. Available from: http://insights.ovid.com/crossref?an=00124743-90000000-98943

19. Nakashima R. Clinical significance of myositis-specific autoantibodies. Immunol Med [Internet], 2018 Jul 3 [cited 2019 Nov 12]; 41(3):103–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30938275 https://doi.org/10.1080/25785826.2018.1531188 PMID: 30938275

20. Solomon J, Swigris JJ, Brown KK. Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol [Internet]. [cited 2019 Nov 12]; 37(1):100–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21390438

21. Platteel ACM, Wevers BA, Lim J, Bakker JA, Bontkes HJ, Curvers J, et al. Frequencies and clinical associations of myositis-related antibodies in The Netherlands: A one-year survey of all Dutch patients. J Transl Autoimmun [Internet]. 2019 Aug 23 [cited 2019 Nov 12];100013. Available from: https://www.sciencedirect.com/science/article/pii/S2589909919300139 https://doi.org/10.1016/j.jtauto.2019.100013 PMID: 32743501

22. Hengstman GJ, Vree Egberts WTM, Seelig HP, Lundberg IE, Moutsopoulos HM, Doria A, et al. Clinical characteristics of patients with myositis and autoantibodies to different antigens of the Mi-2 beta antigen. Ann Rheum Dis [Internet]. 2006 Feb 1 [cited 2019 Nov 12]; 65(2):242–5. Available from: http://ard.bmj.com/cgi/doi/10.1136/ard.2005.040717 PMID: 16410528

23. HANDA T, NAGAI S, KAWABATA D, NAGAO T, TAKEMURA M, KITAICHI M, et al. Long-term Clinical Course of a Patient with Anti-PL-12 Antibody Accompanied by Interstitial Pneumonia and Severe Pulmonary Hypertension. Intern Med [Internet]. 2005 [cited 2019 Nov 14]; 44(4):319–25. Available from: https://www.jstage.jst.go.jp/article/internalmedicine/44/4/4_4_319/_article https://doi.org/10.2169/internalmedicine.44.319 PMID: 15897644

24. LaMedica G, Parodi A, Peris G, Rebora A. Polymyositis and pulmonary fibrosis associated with anti-PL-7 antibody. J Am Acad Dermatol [Internet]. 1988 Sep [cited 2019 Nov 14]; 19(3):567–8. Available from:
32. Arends T, Bunn CC, Beynon HLC, Bernstein RM, Hughes JMB, So AK, et al. Polymyositis, Pulmonary Fibrosis and Autoantibodies to Aminoacyl-tRNA Synthetase Enzymes. QJM [Internet]. 1990 Oct 1 [cited 2019 Nov 14]; 77(1):1019–38. Available from: https://academic.oup.com/qjmed/article-lookup/doi/10.1093/qjmed/77.1.1019 PMID: 2267280

33. Gomez-del Arco P, Perdiguerio E, Yunes-Leites PS, Acín-Pérez R, Zeini M, Garcia-Gómez A, et al. The Chromatin Remodeling Complex Chd4/NuRD Controls Striated Muscle Identity and Metabolic Homeostasis. Cell Metab [Internet]. 2016 May [cited 2019 Dec 2]; 23(5):881–92. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1550413116301590 https://doi.org/10.1016/j.cmet.2016.04.008 PMID: 27166947

34. Mammen AL, Casciola-Rosen LA, Hall JC, Christopher-Stine L, Corse AM, Rosen A. Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum. 2009 Dec; 60(12):3784–93. https://doi.org/10.1002/art.24977 PMID: 19950298

35. Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E, et al. Enhanced autoimmune expression in regenerating muscle cells in idiopathic inflammatory myopath. J Exp Med. 2005 Feb 21; 201(4):591–601. https://doi.org/10.1084/jem.20041367 PMID: 15728237

36. Palmucci S, Roccasalva F, Puglisi S, Torrisi SE, Vindigni V, Mauro LA, et al. Clinical and radiological features of idiopathic interstitial pneumonias (IIPs): a pictorial review. Insights Imaging [Internet]. 2014 Jun 22 [cited 2019 Dec 5]; 5(3):347–64. Available from: http://link.springer.com/10.1007/s13244-014-0335-5 PMID: 24844885

37. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat M-L, Gabbiani G. The Myofibroblast. Am J Pathol [Internet]. 2007 Jun [cited 2019 Dec 5]; 170(6):1807–16. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0002944010613909

38. Heukels P, Moor CC, von der Thüsen JH, Wijnenbeek MS, Kool M. Inflammation and immunity in IPF pathogenesis and treatment. Respir Med [Internet]. 2019 Feb [cited 2019 Dec 5]; 147:79–91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30704705 https://doi.org/10.1016/j.rmed.2018.12.015 PMID: 30704705

39. Luzina IG, Salcedo M V., Rojas-Peña ML., Wyman AE, Galvin JR, Sachdeva A, et al. Transcriptional evidence of immune activation in macroscopically normal-appearing and scarred lung tissues in idiopathic pulmonary fibrosis. Cell Immunol. 2018 Mar 1; 325:1–13. https://doi.org/10.1016/j.cellimm.2018.01.002 PMID: 29329637
40. McDonough JE, Ahangari F, Li Q, Jain S, Verleden SE, Maya JH, et al. Transcriptional regulatory model of fibrosis progression in the human lung. JCI Insight. 2019 Nov 14; 4(22). https://doi.org/10.1172/jci.insight.131597 PMID: 31600171

41. Marchal-Sommé J, Uzunhan Y, Marchand-Adam S, Valeyre D, Soumelis V, Crestani B, et al. Cutting Edge: Nonproliferating Mature Immune Cells Form a Novel Type of Organized Lymphoid Structure in Idiopathic Pulmonary Fibrosis. J Immunol. 2006 May 15; 176(10):5735–9. https://doi.org/10.4049/jimmunol.176.10.5735 PMID: 16670278

42. Hiepe F, Dömer T. Autoantikörper und die Zellen, die sie machen. Z Rheumatol [Internet]. 2005 Sep [cited 2019 Dec 5]; 64(6):389–95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16184346 https://doi.org/10.1007/s00393-005-0767-8 PMID: 16184346

43. Kuwana M, Ogura T, Makino S, Homma S, Kondoh Y, Saito A, et al. Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSICS trial. Mod Rheumatol. 2020.

44. Fernandes L, Nasser M, Ahmad K, Cottin V. Interstitial Pneumonia With Autoimmune Features (IPAF). Front Med [Internet]. 2019 Sep 27 [cited 2022 Jul 18]; 6:209. Available from: /pmc/articles/PMC6798044/